CMRX241220P2000
- 0.00
- 0.000.00%
Chimerix Newsroom
WHO Extends Mpox Emergency; Canada Reports First Clade I Case
Express News | World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern
First Mpox Case Linked to African Outbreak Reported in U.S.
Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Chimerix Analyst Ratings
Chimerix's Dordaviprone Shows Promising Efficacy in H3 K27M-mutant Diffuse Glioma With $11 Price Target
Press Release: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript Summary
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript
TD Cowen Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $8
JonesTrading Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $5
Chimerix's Positive Phase 3 Trial Progress and Strong Financial Position Justify 'Buy' Rating
Chimerix Reports Q3 2024 Results and Study Progress
Chimerix: Q3 Earnings Snapshot
Chimerix | 10-Q: Q3 2024 Earnings Report
Express News | Chimerix Inc: Phase 3 Action Study on-Track With First Interim Overall Survival Data Expected Q3 2025
Chimerix | 8-K: Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update
Chimerix GAAP EPS of -$0.26 Misses by $0.02, Revenue of $0.02M Misses by $0.29M
Chimerix Q3 2024 GAAP EPS $(0.26) Misses $(0.24) Estimate, Sales $26.00K Miss $75.00K Estimate
Express News | Chimerix Q3 Net Income USD -22.9 Million